Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.?
Info & Links
CEO
David Chang
Headquarters
210 EAST GRAND AVENUE SOUTH SAN FRANCISCO, CA 94080, UNITED STATES
Allogene Therapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
318.89M
Enterprise Value
281.08M
Enterprise Value/EBITDA(ttm)
-1.28
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
1.08
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
0.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
0.00%
Return on Equity(ttm)
-57.79%
Return on Invested Capital(ttm)
-57.61%
Return on Assets(ttm)
-43.11%
Income Statement
Revenue(ttm)
0.00
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
0.00
EBITDA(ttm)3
-219.92M
Net Income Available to Common(ttm)
-212.01M
Diluted EPS(ttm)
-0.98
Share Statistics
Beta (5Y Monthly)
0.47
52-Week Change
-31.16%
S&P 500 52-Week Change
15.47%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
224.73M
Dividend Yield
0.00%
Float4
195.07M
% Held by Insiders
13.20%
% Held by Institutions
83.63%
Balance Sheet
Total Cash(mrq)
252.19M
Total Cash Per Share(mrq)
1.12
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
8.19%
Quick Ratio(mrq)
8.19%
Book Value Per Share(mrq)
1.41
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.55
Free Cash Flow(ytd)
-122.03M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.